Since then, new evidence has come from RCTs (including NOACs and stronger P2Y12 inhibitors), subsequently leading to the preferred use of NOACs for the management of AF [1] and ticagrelor/prasugrel for ACS [3, 4]. The gene discussed is P2RY12; the disease is atrial fibrillation.